AI healthcare: which company is the most profitable?

       AI+medical involves AI-assisted diagnosis, intelligent medical equipment, medical big data analysis, AI pharmaceuticals, telemedicine services and other aspects.

Profitability is usually expressed as the amount of corporate revenue and its level in a certain period of time. Profitability analysis is an in-depth analysis of the company's profit margin.

This article is the [Profitability] article of the corporate value series. A total of 30 AI medical companies were selected as research samples, and the return on net assets, gross profit margin, net profit margin and other evaluation indicators were used.

The data is based on history and does not represent future trends; it is only for static analysis and does not constitute investment advice.

Top 10 AI medical profitability companies:

No. 10 Hongbo Pharmaceutical

Industry segment: medical R&D outsourcing

Profitability: ROE 13.61%, gross profit margin 35.48%, net profit margin 12.71%

Performance forecast: ROE has dropped to 3.39% in the past three years, and the latest forecast average is 2.46%

Main products: Drug discovery is the main source of income, accounting for 59.54% of revenue, and gross profit margin is 33.17%

Company highlights: The PR-GPT multimodal large-scale language AI model built by Hongbo Pharmaceutical is mainly used to process and generate human language and chemical molecule descriptions.

No. 9 Chengdu Pioneer

Industry segment: medical R&D outsourcing

Profitability: ROE 3.30%, gross profit margin 47.98%, net profit margin 13.04%

Performance forecast: ROE has fluctuated between 1% and 5% in the past three years, with the latest forecast average of 3.60%

Main products: New drug R&D services are the main source of income, accounting for 99.93% of revenue, with a gross profit margin of 46.59%

Company highlights: The results of the first phase of cooperation between Chengdu Pioneer and Tencent AILab have been published in ACSOmega, and both parties share a molecular skeleton transition system based on AI technology.

No. 8 Neusoft Group

Industry segment: IT services

Profitability: ROE 3.44%, gross profit margin 23.71%, net profit margin 2.94%

Performance forecast: ROE has been as high as 13.15% in the past three years, and the latest forecast average is 2.92%

Main products: Smart car interconnection is the main source of income, accounting for 40.24% of revenue, and gross profit margin is 16.22%

Company highlights: Neusoft Group established Neusoft Magic Technology Research Institute, based on LLM-SE Neusoft large language model system engineering, and successively launched the vertical domain large model "Tianyi Medical Field Large Model" in the field of "AI+Medical".

No. 7 Yaoshi Technology

Industry segment: medical R&D outsourcing

Profitability: ROE 14.07%, gross profit margin 45.38%, net profit margin 24.60%

Performance forecast: ROE has dropped to 7.16% in the past three years, and the latest forecast average is 6.70%

Main products: Products and services in the drug development and commercialization stages are the main source of income, accounting for 77.61% of revenue and a gross profit margin of 33.99%

Company highlights: Yaoshi Technology breaks through the basic concept of traditional ultra-large capacity virtual compound libraries. First, it uses artificial intelligence machine learning algorithms to develop a unique dynamic chemical space based on molecular building blocks and effective chemical reactions.

No. 6 Runda Medical

Industry segment: pharmaceutical distribution

Profitability: ROE 9.87%, gross profit margin 27.19%, net profit margin 5.94%

Performance forecast: ROE has dropped to 6.84% in the past three years, and the latest forecast average is 6.89%

Main products: Reagents and other consumables are the main source of income, accounting for 94.37% of revenue, and gross profit margin is 27.24%

Company highlights: Runda Medical develops a large model of inclusive AI medical services based on the development of Huijian products and Huawei Pangu large model technology.

No. 5 Haoyuan Pharmaceutical

Industry segment: medical R&D outsourcing

Profitability: ROE 10.47%, gross profit margin 50.24%, net profit margin 13.50%

Performance forecast: ROE has dropped to 5.22% in the past three years, and the latest forecast average is 6.67%

Main products: Molecular building blocks, tool compounds and biochemical reagents are the main sources of income, accounting for 66.28% of revenue, and gross profit margin 59.54%

Company highlights: Haoyuan Pharmaceutical uses the AI model to help new drug research and development break through technical barriers and promote the application of artificial intelligence in the drug research and development stage.

No. 4 Weining Health

Industry segment: vertical application software

Profitability: ROE 5.42%, gross profit margin 45.01%, net profit margin 7.79%

Performance forecast: ROE has fluctuated between 2% and 8% in the past three years, with the latest forecast average of 7.57%

Main products: Software sales are the main source of income, accounting for 56.84% of revenue, and gross profit margin 55.45%

Company highlights: Weining Health released the medical vertical field large model WiNGPT, which is built into the company's products in the form of medical smart assistant WiNEX Copilot.

No. 3 Libang Instruments

Industry segment: medical equipment

Profitability: ROE 12.71%, gross profit margin 56.53%, net profit margin 12.89%

Performance forecast: ROE has fluctuated between 11% and 14% in the past three years, and the latest forecast average is 9.91%

Main products: Patient monitoring is the main source of income, accounting for 26.09% of revenue, and gross profit margin is 55.15%

Company highlights: Taking ultrasound products as an example, Libang Instruments' full-stack analysis system has greatly reduced the computing power threshold requirements while achieving high-efficiency and high-precision diagnosis.

No. 2 Xiangsheng Medical

Industry segment: medical equipment

Profitability: ROE 9.51%, gross profit margin 58.13%, net profit margin 28.78%

Performance forecast: ROE has fluctuated between 8% and 11% in the past three years, and the latest forecast average is 11.91%

Main products: Ultrasound medical imaging equipment is the main source of income, accounting for 89.81% of revenue, and gross profit margin is 57.88%

Company highlights: Xiangsheng Medical SonoAI software has been widely used in high-end cart color ultrasound and new portable product lines in multiple diseases or clinical fields.

No. 1 Twinings Bio

Industry segment: API

Profitability: ROE 8.32%, gross profit margin 26.19%, net profit margin 11.24%

Performance forecast: ROE has risen to 14.33% in the past three years, and the latest forecast average is 17.78%

Main products: Pharmaceutical intermediates are the main source of income, accounting for 93.35% of revenue, and gross profit margin is 37.27%

Company highlights: In the future, Twinings Bio will use AI to assist in the research and development of synthetic biology and cooperate in the development of new products, combining artificial intelligence with the company's existing industries.